# US 2024/0183852 A1 · Multiplex immunoassay for the detection of mycoplasma bovis infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0183852 A1
- Document ID: US20240183852A1
- Status: Published application
- Kind: A1
- Application number: 18/285,490
- Filed: 2022-04-08
- Published: 2024-06-06
- Earliest claimed: 2021-04-09
- Assignees: Pictor Limited; The University of Melbourne
- Applicants: Pictor Limited; The University of Melbourne
- Inventors: Anna Kanci Condello; Glenn Francis Browning; James Yazah Adamu; Jimena Maria Tejerina; Kelly Anne Tivendale; Wasala Mudiyanselage Nadeeka Jumari Wawegama; Philip Francis Markham; Sandeep Kumar Vashist
- Web page: https://patentgrep.com/patent/US20240183852A1

## CPC

- G01N 33/56933: {Mycoplasma}
- C07K 14/35: from Mycobacteriaceae (F)
- C07K 16/1253: {from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]}
- G01N 33/54326: {Magnetic particles}
- G01N 33/581: {with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)}
- G01N 33/6854: {Immunoglobulins}
- C12R 2001/35: Mycoplasma
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Mycoplasma bovis infection in cattle is a major production limiting disease of cows and calves. M. bovis can cause a range of conditions in cattle. including mastitis in dairy cows. arthritis in cows and calves. pneumonia in calves, and various other diseases including late-term abortion. The present invention provides methods for detecting multiple anti-M. bovis antibodies in a single multiplex immunoassay.

## Claims

### Claim 1

A substrate comprising at least two capture elements specific for Mycoplasma bovis (M. bovis) on the substrate, each capture element corresponding to and being able to bind a target analyte,
the substrate further optionally comprising a plurality of control elements comprising: a) at least one fiduciary marker, b) at least one negative control to monitor background signal, c) at least one negative control to monitor assay specificity, d) at least one positive colorimetric control, e) at least one positive control to monitor assay performance and any combination thereof.

### Claim 2 (depends on 1)

The substrate of claim 1, wherein the capture elements bind target analytes, wherein the target analytes are indicative of an M. bovis infection.

### Claim 3 (depends on 1)

The substrate of claim 1, wherein the capture element is selected from the group consisting of a protein, lipoprotein, glycoprotein, a protein fragment, a peptide, a polypeptide, a polypeptide fragment, antigen, an antigen fragment, an antigenic determinant, an epitope, a hapten, an immunogen, an immunogen fragment, or any combination thereof.

### Claim 4 (depends on 1)

The substrate of claim 1, wherein the capture element is selected from the group consisting of MilAab (SEQ ID NO: 10), MBOVGP45_310 (SEQ ID NO: 11), MBOVGP45_320 (SEQ ID NO: 12), MBOVGP45_0402 (SEQ ID NO: 13), MBOVGP45_0117 (SEQ ID NO: 14), MBOVGP45_0353 (SEQ ID NO: 15), MBOVGP45_0416 (SEQ ID NO: 16), MBOVGP45_0565 (SEQ ID NO: 17), MBOVGP45_0710-EF (SEQ ID NO: 18), an epitope thereof and a combination thereof.

### Claim 5 (depends on 1)

The substrate of claim 1, wherein the capture element comprises MilAab (SEQ ID NO:10), MBOVPG45_310 (SEQ ID NO:11), MBOVGP45_320 (SEQ ID NO:12), MBOVGP45_0402 (SEQ ID NO:13) and MBOVGP45_0117 (SEQ ID NO:14).

### Claim 6 (depends on 1)

The substrate of claim 1, wherein the target analyte is an antibody or an antibody fragment.

### Claim 7 (depends on 1)

The substrate of claim 1, wherein the substrate is a solid or porous substrate.

### Claim 8 (depends on 7)

The substrate of claim 7, wherein the solid substrate is a paramagnetic bead, microtiter plate, microparticle, or magnetic bead.

### Claim 9 (depends on 1)

A kit for detecting a plurality of target analytes in a sample, comprising a) a substrate of claim 1 and optionally one or both of b) a background reducing reagent, and c) a colorimetric detection system.

### Claim 10 (depends on 9)

The kit of claim 9, further comprising one or more items selected from the group consisting of: a) a wash solution, b) one or more antibodies for detection of antigens, ligands or antibodies bound to the capture elements or for detection of the positive controls, c) software for analyzing captured target analytes, d) a protocol for measuring the presence of target analytes in samples, e) a sample diluent, f) blotting TMB (3,3′,5,5′-tetrarnethylbenzidine) and g) a secondary antibody.

### Claim at position 11

11-15. (canceled)

### Claim 16 (depends on 9)

The kit of claim 9, wherein the colorimetric detection system comprises HRP-labelled anti-bovine IgG Ab.

### Claim 17 (depends on 9)

The kit of claim 9, wherein the secondary antibody comprises at least one anti-bovine IgG antibody.

### Claim 18

(canceled)

### Claim 19 (depends on 18)

The kit of claim 18, wherein the mammal is bovine.

### Claim 20 (depends on 1)

A method for processing a microarray comprising:
a) providing a substrate of claim 1;
b) adding at least one sample to the substrate; and
c) processing the substrate such that a detectable result is given by two or more of i) at least one fiduciary marker, ii) at least one positive colorimetric control, and iii) at least one positive control to monitor assay performance.

### Claim at position 17

21-23. (canceled)

### Claim 24 (depends on 1)

A method for detecting an analyte in a sample comprising a substrate of claim 1, adding at least one sample to the substrate, and processing the substrate such that a detectable result is provided.

### Claim 25

(canceled)

### Claim 26 (depends on 24)

The method of claim 24, wherein the detectable result includes two or more of at least one fiduciary marker, at least one positive colorimetric control, and at least one positive control to detect an analyte in the sample.

### Claim at position 21

27-29. (canceled)

### Claim 30

An isolated peptide selected from the group consisting of MilAab (SEQ ID NO: 10), MBOVGP45_310 (SEQ ID NO: 11),-MBOVGP45_320 (SEQ ID NO: 12), MBOVGP45_0402 (SEQ ID NO: 13), MBOVGP45_0117 (SEQ ID NO:14), MBOVGP45_0353 (SEQ ID NO: 15), MBOVGP45_0416 (SEQ ID NO: 16), MBOVGP45_0565 (SEQ ID NO: 17) or MBOVGP45_0710-EF (SEQ ID NO: 18).

### Claim 31 (depends on 30)

An antibody that binds any one of the isolated peptides of claim 30.

### Claim 32

(canceled)

### Claim 33

A nucleic acid encoding a peptide selected from the group consisting of MBOVGP45_320 (SEQ ID NO: 12), MBOVGP45_0402 (SEQ ID NO: 13), MBOVGP45_0117 (SEQ ID NO:14), MBOVGP45_0353 (SEQ ID NO: 15), MBOVGP45_0416 (SEQ ID NO: 16) or MBOVGP45_0565 (SEQ ID NO: 17).

### Claim 34 (depends on 1)

A method of detecting a Mycoplasma bovis infection in bovine comprising:
a) adding at least one sample to the substrate of claim 1; and
b) processing the substrate such that a detectable result is given by two or more of i) at least one fiduciary marker, ii) at least one positive colorimetric control, and iii) at least one positive control to monitor assay performance, thereby detecting a Mycoplasma bovis infection.

### Claim at position 27

35-36. (canceled)
